Reversible retinal vessel closure from VEGF-induced leukocyte plugging

Area of Science:

• Ophthalmology
• Molecular Biology
• Vascular Biology

Background:

• Clinical trials show vascular endothelial growth factor (VEGF) suppression improves outcomes in ischemic retinopathies like diabetic retinopathy and retinal vein occlusion (RVO).
• The molecular mechanisms underlying these benefits, particularly vessel reperfusion and prevention of closure, are not fully understood.

Purpose of the Study:

• To elucidate the molecular basis for the therapeutic effects of VEGF suppression in ischemic retinopathies.
• To identify specific molecular targets involved in VEGF-mediated vascular pathology.

Main Methods:

• Induction of high retinal VEGF levels in a mouse model.
• Administration of neutralizing antibodies against VEGFR1 and VCAM-1.
• Assessment of leukocyte plugging, vessel closure, hypoxia, NF-κB activity, and gene expression.

Main Results:

• Elevated retinal VEGF caused leukocyte plugging, vessel closure, and hypoxia in mice.
• VEGF suppression reduced leukocyte plugging and promoted reperfusion of closed vessels.
• VEGFR1 activation was crucial for leukocyte recruitment, and VCAM-1 was identified as a key VEGF-induced gene involved in leukocyte plugging.

Conclusions:

• VEGF suppression offers broad benefits in ischemic retinopathies by mitigating leukocyte-driven vascular occlusion.
• VEGFR1 and VCAM-1 are critical molecular targets that, alongside VEGF, contribute to the pathogenesis of RVO and diabetic retinopathy.
• Targeted suppression of VEGFR1 and VCAM-1 may complement VEGF neutralization for improved therapeutic outcomes.